Equillium, Inc. (EQ)
Health Care · clinical-stage autoimmune and inflammatory disease therapeutics · Nasdaq
Clinical-stage biotech developing EQ504, a novel AhR modulator for severe autoimmune and inflammatory disorders.
What Equillium, Inc. does
Equillium is a clinical-stage biotechnology company developing novel therapeutics to treat severe autoimmune and inflammatory disorders. The company's primary focus is advancing EQ504, a novel aryl hydrocarbon receptor (AhR) modulator, through clinical development. To date, Equillium has generated no product sales and has incurred significant operating losses as it invests substantially all efforts in research and development of its product candidates.
Themes: ["autoimmune and inflammatory disorders","AhR modulators","clinical development stage"]
Fundamentals
- Price$2.91 as of 2026-07-10 close
- Market cap$184M as of 2026-07-13
- 1-year return+731.4% as of 2026-07-10 close
- Net margin-19.6% as of 2026-07-13
- ROE-61.4% as of 2026-07-13
- Debt / equity0.00 as of 2026-07-13
- Revenue CAGR (3y)+61.5% SEC XBRL
- Beta1.83 as of 2026-07-13
Key risks (from latest filing)
["Company has not generated any product sales and has accumulated deficit of $221.5 million as of March 31, 2026, requiring significant additional capital raises to fund development","EQ504 Phase 1 proof-of-mechanism study planned to commence mid-2026 with no assurance of favorable data or timely completion","Intensive competition and rapidly changing environment in autoimmune and inflammatory disorder therapeutics with uncertain market acceptance and regulatory approval pathways"]
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.